Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC

About this update from Cardiff Oncology, Inc.

[{"type":"image","alt":"Cardiff Oncology, Inc.","displaySize":"","headline":null,"caption":"Cardiff Oncology, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":89,"url":"https://media.zenfs.com/en/globenewswire.com/c3438e5d34725b0f8f9b8f7493032b71"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/86EIU7QtkFu2zHgjv0tCZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNQ--/https://media.zenfs.com/en/globenewswire.com/c3438e5d34725b0f8f9b8f7493032b71","width":300,"height":89},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/86EIU7QtkFu2zHgjv0tCZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNQ--/https://media.zenfs.com/en/globenewswire.com/c3438e5d34725b0f8f9b8f7493032b71","width":300,"height":89}},"lazy":false},{"type":"text","content":"Updated Phase 2 CRDF-004 data to be presented during ASCO 2026 rapid oral session on June 2, 2026; investor webcast scheduled for June 3, 2026 at 8:30 am ET to review the data","length":175,"tagName":"p"},{"type":"text","content":"SAN DIEGO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced that it will host an investor webcast featuring members of management on June 3, 2026 at 8:30 am ET to review updated data from CRDF-004, a randomized dose-finding Phase 2 clinical trial evaluating onvansertib in combination with standard-of-care regimens (FOLFIRI/bevacizumab or FOLFOX/bevacizumab) in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC).","length":584,"tagName":"p"},{"type":"text","content":"The updated CRDF-004 data will first be presented during a rapid oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on June 2, 2026 at 8:00 am CT/9:00 am ET and will build on the CRDF-004 data previously presented in January 2026. More details about the oral presentation are available on the Company’s website here and the full abstract is now available on the ASCO website.","length":414,"tagName":"p"},{"type":"text","content":"Investor Webcast DetailsThe investor webcast will take place on June 3 at 8:30 am ET. To register for and access the live webcast, please visit the “Events” page of the Cardiff Oncology website.","length":195,"tagName":"p"},{"type":"text","content":"About Onvansertib Onvansertib...

More updates from Cardiff Oncology, Inc.